Business, energy, technology, markets and global industry news from Business News Today

clinical trials

PharmaDeviceNews clinical trials
Representative image of an ophthalmology exam setting as Minghui Pharmaceutical’s MHB018A data sharpen interest in subcutaneous IGF-1R antibody therapy for thyroid eye disease.
Pharma & Biotech

Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?

Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.

Read More
Representative image: A paediatric audiology assessment highlights the clinical focus behind Sensorion’s SENS-601 gene therapy program for GJB2-related hearing loss.
Pharma & Biotech

Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets

Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.

Read More
Representative image of CNS drug development and neuroscience research, highlighting Enveric Biosciences’ EB-003 push toward clinical-stage neuroplastogen testing.
Pharma & Biotech

Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development

Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More
Representative image of clinical research teams reviewing trial performance data as ICON plc’s restatement raises wider questions over CRO trust and pharma outsourcing risk.
Features & Analysis

Can ICON turn governance repair into renewed momentum for clinical research services?

ICON’s restatement and backlog reset test CRO confidence as pharma sponsors weigh execution risk, trial demand and 2026 recovery signals.

Read More
Pharma & Biotech

How Zifo’s AI authoring platform could reshape clinical and CMC documentation

Regulatory teams need speed, but AI needs auditability. Zifo’s authoring platform tests whether pharma can have both.

Read More
Medical Devices & Diagnostics

Can Reprieve Cardiovascular’s FASTR data change acute heart failure decongestion?

Heart failure care needs faster decongestion without kidney harm. Reprieve’s FASTR data now face the pivotal trial test.

Read More
Pharma & Biotech

Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight

FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.

Read More
Pharma & Biotech

Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF

Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.

Read More
Pharma & Biotech

AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race

A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.

Read More